Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Epstein-Barr Virus Infections 6Sarcoma, Kaposi 4Lymphoproliferative Disorders 4Nasopharyngeal Carcinoma 3Glioblastoma 3Cytomegalovirus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Neoplasm Metastasis 1Multiple Acyl Coenzyme A Dehydrogenase Deficiency 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Herpes Simplex 1Head and Neck Neoplasms 1HIV Infections 1Fatigue Syndrome, Chronic 1Fatigue 1EBV Lymphomas 1

Interventions

Valganciclovir 1Matrix-M 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Herpes Simplex × Valganciclovir × Clear all
NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Stanford University

Phase 1/2 Completed
30 enrolled

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡